Traws Pharma, Inc.
TRAW · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $3 | $0 | $0 | $0 |
| % Growth | 4,694.7% | 1.8% | -50.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $3 | $0 | $0 | $0 |
| % Margin | 100% | 96.5% | 100% | 96.5% |
| R&D Expenses | $5 | $5 | $2 | $5 |
| G&A Expenses | $3 | $3 | $3 | $3 |
| SG&A Expenses | $3 | $3 | $3 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$4 | $0 | $0 | $0 |
| Operating Expenses | $4 | $9 | $5 | $10 |
| Operating Income | -$1 | -$9 | -$5 | -$10 |
| % Margin | -45.7% | -14,975.4% | -9,307.1% | -8,452.2% |
| Other Income/Exp. Net | $0 | $0 | $0 | $1 |
| Pre-Tax Income | -$1 | -$8 | -$5 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$8 | -$5 | -$9 |
| % Margin | -22.9% | -14,868.4% | -8,898.2% | -7,896.5% |
| EPS | -0.11 | -8.81 | -5.92 | -10.621 |
| % Growth | 98.8% | -48.8% | 44.3% | – |
| EPS Diluted | -0.11 | -8.81 | -5.92 | -10.621 |
| Weighted Avg Shares Out | 6 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 6 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$8 | -$5 | -$9 |
| % Margin | -91.3% | -14,864.9% | -9,300% | -8,198.2% |